Search

Your search keyword '"Gorrochategui, J."' showing total 3 results
Start Over Author "Gorrochategui, J." Publisher ferrata storti foundation
3 results on '"Gorrochategui, J."'

2. VALIDATION OF PRECISION MEDICINE TEST FOR ACUTE MYELOID LEUKEMIA IN AN OBSERVATIONAL CLINICAL TRIAL

Author

Montesinos, P., Ballesteros, J., Martinez Cuadron, D., Joaquin Martinez-Lopez, Serrano, J., Perez Oteyza, J., Bergua, J., Tormo, M., Fernandez, P., Vidriales, M. B., Vives, S., Rodriguez-Macias, G., Herrera, P., Garcia, R., Fernandez, M. A., Lavilla, E., Perez Simon, J. A., Jimenez, S., Simiele, A., Gonzalez, A., Gonzalez, B., Burgaleta, C., Hernandez Rivas, J. A., Colorado, M., Sierra, J., Alonso, A., Bethancourt, C., Vera, J. A., Lopez, J. A., Bautista, G., Navas, B., Amador, M. L., Mora Casado, M. A., La Fuente, A., Ramos, F., Cervero, C. J., Rayon, C., Lopez, A., Marti, E., Salamero, O., Olave, T., Gorrochategui, J., Rojas, J. L., Gomez, C., Hernandez, P., Robles, A., Villoria, J., Moscardo, F., Troconiz, I., and Sanz, M. A.

Published
2017

3. Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms.

Author

Cortés AA, Diaz RA, Hernández-Campo P, Gorrochategui J, Primo D, Robles A, Morales ML, Ballesteros J, Rapado I, Gallardo M, Linares M, and Martínez-López J

Subjects
Aged, Aged, 80 and over, Female, Humans, Leukocytes, Mononuclear pathology, Male, Middle Aged, Myeloproliferative Disorders pathology, Nitriles, Prednisone administration & dosage, Primary Myelofibrosis pathology, Prognosis, Protein Array Analysis, Pyrazoles administration & dosage, Pyrimidines administration & dosage, Tumor Cells, Cultured, Antineoplastic Combined Chemotherapy Protocols pharmacology, Drug Synergism, Leukocytes, Mononuclear drug effects, Myeloproliferative Disorders drug therapy, Primary Myelofibrosis drug therapy
Abstract

Ruxolitinib is the front-line non-palliative treatment for myelofibrosis (MF). However, a significant number of patients lose or present suboptimal response, are resistant or have unacceptable toxicity. In an attempt to improve response and avoid the adverse effects of this drug, we evaluated the combination of 17 drugs with ruxolitinib in ex vivo models of peripheral blood mononuclear cells from MF patients and cell lines. We found that the combination ruxolitinib and nilotinib had a synergistic effect against MF cells (ΔEC 50 nilotinib, -21.6%). Moreover, the addition of prednisone to combined ruxolitinib/nilotinib improved the synergistic effect in all MF samples studied. We evaluated the molecular mechanisms of combined ruxolitinib/nilotinib/prednisone and observed inhibition of JAK/STAT (STAT5, 69.2+11.8% inhibition) and MAPK (ERK, 29.4+4.5% inhibition) signaling pathways. Furthermore, we found that the triple therapy combination inhibited collagen protein and COL1A1 gene expression in human bone marrow mesenchymal cells. Taken together, we provide evidence that combined ruxolitinib/nilotinib/prednisone is a potential therapy for MF, possibly through the anti-fibrotic effect of nilotinib, the immunomodulatory effect of ruxolitinib and prednisone, and the anti-proliferative effect of ruxolitinib. This combination will be further investigated in a phase Ib/II clinical trial in MF., (Copyright© 2019 Ferrata Storti Foundation.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results